Shares of Summit Therapeutics PLC (NASDAQ:SMMT) have received a consensus recommendation of “Buy” from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $28.25.

Several research analysts recently commented on SMMT shares. Oppenheimer Holdings, Inc. reiterated a “buy” rating on shares of Summit Therapeutics PLC in a research note on Wednesday, March 22nd. Zacks Investment Research lowered shares of Summit Therapeutics PLC from a “buy” rating to a “hold” rating in a research note on Saturday, April 1st. ValuEngine upgraded shares of Summit Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, June 6th. Finally, Canaccord Genuity restated a “buy” rating and set a $28.00 price target on shares of Summit Therapeutics PLC in a research note on Friday.

A hedge fund recently bought a new stake in Summit Therapeutics PLC stock. Acadian Asset Management LLC purchased a new position in shares of Summit Therapeutics PLC (NASDAQ:SMMT) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,850 shares of the company’s stock, valued at approximately $171,000. Acadian Asset Management LLC owned 0.10% of Summit Therapeutics PLC as of its most recent filing with the SEC. 21.86% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Summit Therapeutics PLC (SMMT) traded down 0.2483% during midday trading on Monday, hitting $10.9695. 725 shares of the company traded hands. The stock’s market capitalization is $135.78 million. Summit Therapeutics PLC has a 52 week low of $5.31 and a 52 week high of $19.75. The company has a 50-day moving average price of $11.16 and a 200-day moving average price of $11.07.

ILLEGAL ACTIVITY WARNING: “Summit Therapeutics PLC (SMMT) Given Consensus Rating of “Buy” by Analysts” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/06/19/summit-therapeutics-plc-smmt-given-consensus-rating-of-buy-by-analysts.html.

About Summit Therapeutics PLC

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.